BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sun J, Park C, Guenthner N, Gurley S, Zhang L, Lubben B, Adebayo O, Bash H, Chen Y, Maksimos M, Muz B, Azab AK. Tumor-associated macrophages in multiple myeloma: advances in biology and therapy. J Immunother Cancer 2022;10:e003975. [DOI: 10.1136/jitc-2021-003975] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Tang W, Xu J, Xu C. Noncoding RNAs in the crosstalk between multiple myeloma cells and bone marrow microenvironment. Cancer Lett 2023;556:216081. [PMID: 36739065 DOI: 10.1016/j.canlet.2023.216081] [Reference Citation Analysis]
2 Dilly S, Romero M, Solier S, Feron O, Dessy C, Slama Schwok A. Targeting M2 Macrophages with a Novel NADPH Oxidase Inhibitor. Antioxidants (Basel) 2023;12. [PMID: 36830003 DOI: 10.3390/antiox12020440] [Reference Citation Analysis]
3 Gu GJ, Chung H, Park JY, Yoo R, Im HJ, Choi H, Lee YS, Seok SH. Mannosylated-serum albumin nanoparticle imaging to monitor tumor-associated macrophages under anti-PD1 treatment. J Nanobiotechnology 2023;21:31. [PMID: 36707872 DOI: 10.1186/s12951-023-01791-9] [Reference Citation Analysis]
4 Ehlers FAI, Mahaweni NM, van de Waterweg Berends A, Saya T, Bos GMJ, Wieten L. Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages. Cancer Immunol Immunother 2023. [PMID: 36656341 DOI: 10.1007/s00262-022-03365-4] [Reference Citation Analysis]
5 Plano F, Corsale AM, Gigliotta E, Camarda G, Vullo C, Di Simone M, Shekarkar Azgomi M, Speciale M, Carlisi M, Caccamo N, Dieli F, Meraviglia S, Siragusa S, Botta C. Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again. Hematol Rep 2023;15:23-49. [PMID: 36648882 DOI: 10.3390/hematolrep15010004] [Reference Citation Analysis]
6 Aksoy O, Lind J, Sunder-Plaßmann V, Vallet S, Podar K. Bone marrow microenvironment- induced regulation of Bcl-2 family members in multiple myeloma (MM): Therapeutic implications. Cytokine 2023;161:156062. [PMID: 36332463 DOI: 10.1016/j.cyto.2022.156062] [Reference Citation Analysis]
7 Zhang X, Zhang H, Lan H, Wu J, Xiao Y. CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies. Front Immunol 2023;14:1101495. [PMID: 36891310 DOI: 10.3389/fimmu.2023.1101495] [Reference Citation Analysis]
8 Bertuglia G, Cani L, Larocca A, Gay F, D'Agostino M. Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma? Int J Mol Sci 2022;23. [PMID: 36555520 DOI: 10.3390/ijms232415879] [Reference Citation Analysis]
9 Ho M, Xiao A, Yi D, Zanwar S, Bianchi G. Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment. Curr Oncol 2022;29:8975-9005. [PMID: 36421358 DOI: 10.3390/curroncol29110705] [Reference Citation Analysis]
10 Wang SSY, Chng WJ, Liu H, de Mel S. Tumor-Associated Macrophages and Related Myelomonocytic Cells in the Tumor Microenvironment of Multiple Myeloma. Cancers (Basel) 2022;14. [PMID: 36428745 DOI: 10.3390/cancers14225654] [Reference Citation Analysis]
11 Yue Y, Cao Y, Wang F, Zhang N, Qi Z, Mao X, Guo S, Li F, Guo Y, Lin Y, Dong W, Huang Y, Gu W. Bortezomib-resistant multiple myeloma patient-derived xenograft is sensitive to anti-CD47 therapy. Leuk Res 2022;122:106949. [PMID: 36113267 DOI: 10.1016/j.leukres.2022.106949] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Li W, Wang F, Guo R, Bian Z, Song Y. Targeting macrophages in hematological malignancies: recent advances and future directions. J Hematol Oncol 2022;15:110. [PMID: 35978372 DOI: 10.1186/s13045-022-01328-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Hervás-salcedo R, Martín-antonio B. A Journey through the Inter-Cellular Interactions in the Bone Marrow in Multiple Myeloma: Implications for the Next Generation of Treatments. Cancers 2022;14:3796. [DOI: 10.3390/cancers14153796] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Wang J, Jin J, Chen T, Zhou Q. Curcumol Synergizes with Cisplatin in Osteosarcoma by Inhibiting M2-like Polarization of Tumor-Associated Macrophages. Molecules 2022;27:4345. [DOI: 10.3390/molecules27144345] [Reference Citation Analysis]
15 Martelli AM, Paganelli F, Evangelisti C, Chiarini F, Mccubrey JA. Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies. Cells 2022;11:1812. [DOI: 10.3390/cells11111812] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Chabeli MS, Wang X, Yinghao L, Chen C, Yang C, Shou Y, Wang S, Chen K. Similarities between wound re-epithelialization and Metastasis in ESCC and the crucial involvement of macrophages: A review. Cancer Treatment and Research Communications 2022;32:100621. [DOI: 10.1016/j.ctarc.2022.100621] [Reference Citation Analysis]